VascVersa Reaches Major Angicyte® Manufacturing Milestone
Near-Billion Cell Angicyte® Production in Major Manufacturing Breakthrough VascVersa is pleased to announce a significant manufacturing milestone for its proprietary Angicyte® platform, successfully demonstrating scalable production using the Corning Ascent® Fixed Bed Bioreactor System. Initial manufacturing studies generated almost one billion Angicyte® cells, with further optimisation expected to enable production yields significantly beyond these levels. This achievement validates a scalable, automated and closed-system manufacturing approach capable of supporting any future commercial demand for the research platform and clinical supply.
Compared with traditional cell culture methods, the Corning Ascent® platform offers enhanced consistency, reduced manual handling, lower contamination risk, improved process efficiency and significantly reduced consumable waste, supporting a more sustainable manufacturing process. Reaching this scale represents a major step forward for VascVersa, substantially de-risking future manufacturing requirements and strengthening the commercial scale, partnering potential of the Angicyte® platform as the company advances into strategic partnerships.



